Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/30/2022 | $3.10 | Buy | Citigroup |
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on Thursday, May 15, 2025 featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the United States. Representatives from participating companies based in China, Hong Kong, Philippines, Denmark, Germany, South Africa, Switzerland, Sweden, and the United Kingdom will respond to questions during formal presentations. The conference is targeted to all categories of investors and analysts interested in international companies. There is no fee for participants to log in, attend live pr
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on Thursday, May 15, 2025 featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the United States. Representatives from participating companies based in China, Hong Kong, Philippines, Denmark, Germany, South Africa, Switzerland, Sweden, and the United Kingdom will respond to questions during formal presentations. The conference is targeted to all categories of investors and analysts interested in international companies. There is no fee for participants to log in, attend live pr
BEIJING, April 28, 2025 /PRNewswire/ -- iHuman Inc. (NYSE:IH) ("iHuman" or the "Company"), a leading provider of tech-powered, intellectual development products in China, today announced that it filed its annual report on Form 20-F for the year ended December 31, 2024 with the U.S. Securities and Exchange Commission on April 28, 2025. The annual report on Form 20-F is available on the Company's investor relations website at https://ir.ihuman.com/. iHuman will provide a hard copy of its annual report on Form 20-F containing complete audited financial statements for the year ended December 31, 2024, free of charge, to its shareholders and ADS holders upon request. Requests should be directed t
SC 13G/A - iHuman Inc. (0001814423) (Subject)
SC 13G/A - iHuman Inc. (0001814423) (Subject)
SC 13G - iHuman Inc. (0001814423) (Subject)
Citigroup resumed coverage of iHuman with a rating of Buy and set a new price target of $3.10
20-F - iHuman Inc. (0001814423) (Filer)
6-K - iHuman Inc. (0001814423) (Filer)
6-K - iHuman Inc. (0001814423) (Filer)
BEIJING, March 25, 2025 /PRNewswire/ -- iHuman Inc. (NYSE:IH) ("iHuman" or the "Company"), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2024. Fourth Quarter 2024 Highlights Revenues were RMB232.7 million (US$31.9 million), compared with RMB250.4 million in the same period last year.Gross profit was RMB156.4 million (US$21.4 million), compared with RMB178.2 million in the same period last year.Operating income was RMB14.9 million (US$2.0 m
BEIJING, Dec. 26, 2024 /PRNewswire/ -- iHuman Inc. (NYSE:IH) ("iHuman" or the "Company"), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights Revenues were RMB239.4 million (US$34.1 million), compared with RMB261.5 million in the same period last year.Gross profit was RMB163.9 million (US$23.4 million), compared with RMB186.6 million in the same period last year.Operating income was RMB20.7 million (US$2.9 million), compare
BEIJING, Sept. 27, 2024 /PRNewswire/ -- iHuman Inc. (NYSE:IH) ("iHuman" or the "Company"), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Highlights Revenues were RMB215.1 million (US$29.6 million), compared with RMB241.0 million in the same period last year.Gross profit was RMB151.7 million (US$20.9 million), compared with RMB170.8 million in the same period last year.Operating income was RMB18.8 million (US$2.6 million), compared wi